{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P55036",
      "entity_text" : "AF",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:446013",
      "entity_text" : "FDA",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Despite concerns about once-a-day administration of a drug with a relatively short half-life, rivaroxaban was approved by the FDA for stroke prevention for AF patients in November 2011.",
  "reading_complete" : "2020-08-05T22:46:05Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:42:05Z",
  "trigger" : "prevention",
  "evidence" : [ "FDA for stroke prevention for AF" ],
  "pmc_id" : "4422295",
  "score" : 0
}